Medication used to treat non-small cell lung cancer that has metastasized, may benefit patients with metastatic brain cancers, according to a new review and analysis led by researchers at St. Michael's Hospital of Unity Health Toronto and Harvard Medical School.
Published in iJAMA Network Open/i, the research hones in on osimertinib, a treatment recently approved in North America as a therapy for metastatic non-small cell lung cancer with a specific mutation.
In a meta-analysis of 15 studies ...
Medication used to treat non-small cell lung cancer that has metastasized, may benefit patients with metastatic brain cancers, according to a new review and analysis led by researchers at St. Michael's Hospital of Unity Health Toronto and Harvard Medical School.
Published in iJAMA Network Open/i, the research hones in on osimertinib, a treatment recently approved in North America as a therapy for metastatic non-small cell lung cancer with a specific mutation.
In a meta-analysis of 15 studies ...